戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 transcriptional programme similar to that of germ cell tumours.
2 chemotherapy-induced apoptosis in testicular germ cell tumours.
3 elatively frequent loss of heterozygosity in germ cell tumours.
4 ng response assessment for patients with CNS germ cell tumours.
5 better international clinical trials for CNS germ cell tumours.
6 miology, genetics, and biology of testicular germ cell tumours.
7 s in the clinical management of intracranial germ-cell tumours.
8 cal management of patients with intracranial germ-cell tumours.
9  progression-free survival for patients with germ-cell tumours.
10 maeric embryos, and is associated with human germ-cell tumours.
11  cryptorchidism, risk factors for testicular germ-cell tumours.
12  34 patients with cancer, 53% had testicular germ-cell tumours.
13 eview the assessment and management of early germ-cell tumours.
14 e of approaches offer high survival in early germ-cell tumours.
15 tility and increases risk for development of germ-cell tumours.
16 5% CI 20.9-27.5]) and lowest in survivors of germ cell tumours (14.0 [11.5-16.6]).
17 ere defined for the most common sites of CNS germ cell tumour and for the definition of locoregional
18 ise the consensus on how to treat testicular germ cell tumours and focus on a few controversies and i
19        Differentiated tissues within ovarian germ cell tumours and in testicular teratomas lacked det
20 ntly overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the blad
21 ion or death in patients with poor prognosis germ-cell tumours and an unfavourable tumour marker decl
22                                   Testicular germ cell tumours are at the crossroads of developmental
23             In contrast, advanced testicular germ cell tumours are cured in over 80% of patients usin
24                                   Testicular germ cell tumours are highly sensitive to radiotherapy a
25                                   Testicular germ cell tumours are hypersentive to chemotherapy and c
26                                      Ovarian germ cell tumours are rare, but curable at all stages of
27                                              Germ-cell tumours are a heterogeneous group of neoplasms
28                      Up to 80% of metastatic germ-cell tumours are curable with conventional chemothe
29                                Patients with germ-cell tumours are managed by a diverse array of spec
30                               Poor prognosis germ-cell tumours are only cured in about half of patien
31  the results obtained in treating metastatic germ-cell tumours are superior to those with other solid
32 operitoneal, or mediastinal non-seminomatous germ cell tumours based on histological findings or clin
33        Management of paediatric extracranial germ-cell tumours carries a unique set of challenges.
34 expressed ectopically in the 833K testicular germ cell tumour cell line.
35                                   Paediatric germ-cell tumours differ from the adolescent and adult d
36 a indicating fewer second primary testicular germ-cell tumours favour carboplatin use, these findings
37                                              Germ cell tumours (GCTs) are a collection of benign and
38                          Relapsed testicular germ cell tumours (GCTs) might be cured with salvage che
39 opting practices developed for managing male germ cell tumours (GCTs).
40                                              Germ-cell tumours (GCTs) are derived from germ cells and
41 rasellar masses, such as craniopharyngiomas, germ cell tumours, gliomas, cysts of Rathke's pouch and
42 stratification, and treatment approaches for germ-cell tumours have evolved disparately along several
43                                 Intracranial germ cell tumours (IGCTs) are a group of rare heterogene
44  cells (PGCs), as well as the suppression of germ cell tumours in mice.
45               The management of intracranial germ-cell tumours is complex because of varied clinical
46  of in certain pathological contexts such as germ-cell tumours, melanoma or human immunodeficiency vi
47 Fewer than 70 new cases of malignant ovarian germ cell tumours (MOGCTs) are seen each year in the UK.
48 rs, the malignant cells in 73% of testicular germ-cell tumours (seminomas and teratomas), expressed h
49 ovarian cancers, including malignant ovarian germ cell tumours, sex cord-stromal tumours, and small c
50     Tumours within this group are testicular germ-cell tumours (such as benign teratoma, epidermoid c
51 icipants of the 2013 Third International CNS Germ Cell Tumour Symposium (Cambridge, UK) agreed to und
52                                   Testicular germ cell tumour (TGCT) is the most common cancer in you
53             A sizable fraction of testicular germ cell tumour (TGCT) risk is expected to be explained
54 identified multiple risk loci for testicular germ cell tumour (TGCT), revealing a polygenic model of
55  of the genetic susceptibility to testicular germ cell tumour (TGCT).
56 sease is a strong risk factor for testicular germ cell tumour (TGCT).
57                                   Testicular germ cell tumours (TGCT), which comprise seminoma and no
58                                   Testicular germ-cell tumours (TGCT) affect 1 in 500 men and are the
59                                   Testicular germ cell tumours (TGCTs) are histologically heterogeneo
60                                   Testicular germ cell tumours (TGCTs) are the most common cancer in
61                        While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity
62                     Post-pubertal testicular germ-cell tumours (TGCTs) can present with a variety of
63                                   Testicular germ-cell tumours (TGCTs) represent the model of a curab
64 es that control susceptibility to testicular germ-cell tumours (TGCTs), the most common cancer affect
65                          In the second mixed germ cell tumour, the NSTGCT component was methylated fo
66                    Furthermore, in two mixed germ cell tumours, the NSTGCT component for one demonstr
67  of response to therapy in patients with CNS germ cell tumours to be more consistent, and facilitate
68               New, second primary testicular germ-cell tumours were reported in ten patients allocate
69 tements encompassing aspects of intracranial germ-cell tumour work-up, staging, treatment, and follow